Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.

Date publication

avril 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
Ganame S, Walter T, Durand A, Lièvre A, Tougeron D, Scoazec JY, Baudin E, Lepage C, Boussari O, Hadoux J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40340189

Résumé

Randomized trials are very challenging to perform in rare cancers such as gastro-enteropancreatic neuroendocrine carcinomas. We hypothesized that the randomized BEVANEC trial of FOLFIRI + /- bevacizumab could have been designed with an external control arm (ECA) and led to similar results.

Mots clés

(hybrid) external control arm, FOLFIRI, Historical data, Inverse probability weighting, Neuroendocrine carcinoma, Propensity score, Randomization algorithm

Référence

Eur J Cancer. 2025 04 30;:115450